Biofourmis

Biofourmis is a biotechnology company based in Boston, Massachusetts, founded in 2015. It specializes in personalized care and therapies through the use of digital therapeutics. The company develops and delivers clinically validated software-based therapeutics that enhance patient outcomes. Biofourmis has created a predictive health analytics platform that analyzes physiology data gathered from clinical-grade wearables. Utilizing artificial intelligence, this platform integrates and interprets continuous physiological data to identify personalized patterns and predict potential clinical exacerbations. By enabling medical professionals to intervene days before critical events occur, Biofourmis aims to improve patient care and provide cost-effective solutions for healthcare providers.

Omar Ishrak Ph.D

Chairman

2 past transactions

Gaido

Acquisition in 2020
Gaido Health is a technology company that develops an AI-driven platform focused on the continuous monitoring of post-discharge oncology patients. The platform employs proprietary machine learning algorithms to monitor patient health, aiming to detect early signs of deterioration. By concentrating on post-discharge oncology care, Gaido Health enhances the quality of care and outcomes for patients, allowing clinicians to quickly triage and efficiently follow up with those identified as high-risk. The company's innovative approach addresses the critical need for improved patient management following hospital discharge, ultimately supporting better clinical decision-making and patient health.

Biovotion

Acquisition in 2019
Biovotion has developed an accurate, wearable sensing technology, that allows for medical-quality vital sign monitoring (VSM) in daily life. The platform combines medical-quality VSM with design, wearability, convenience, and prices of the consumer market. The system (multi-sensor platform plus sophisticated algorithms) is intergrated into cloud infrastructures to provide users with data on par with standard hospital systems and can be stepwise expanded with additional physiological parameters. Current parameters include heart rate, blood oxygenation, blood perfusion, temperature and movement/activity. The first VSM generation is also expected to include heart rate variability, respiratory rate, energy expenditure, and sleep and stress monitoring. The management team is internationally recognised for its expertise in wearable monitoring. The company holds a broad IP portfolio.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.